Olaparib paved the way for the clinical application of PARPi and was the first compound to receive US Food and Drug Administration approval in 2014 as a maintenance treatment for advanced ovarian cancer (OC) with germline breast cancer gene 1/2 (BRCA1/2) mutations in patients with three or more unsuccessful lines of chemotherapy. This evidence concerns the gene BRCA1 and breast carcinoma.